• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • AbbVie acquires STING pathway-focused Mavupharma pharmaceutical-technology
    July 17, 2019
    Chicago-based AbbVie has announced its acquisition of Seattle-based oncology drug discovery company Mavupharma. The financial terms of the transaction were not disclosed.
  • AbbVie Acquires Mavupharma americanpharmaceuticalreview
    July 17, 2019
    AbbVie has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
  • Frazier-Backed Mavupharma Scores $20M to Fund STING Program biospace
    November 30, 2017
    Frazier-backed Mavupharma secures $20M in Series A financing to fund STING program

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service